



03/30/99

09231474.033099

JC649 U.S. PTO

UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.: DM-6958

First Named Inventor : RAJOPADHYE ET AL.

Express Mail Label No.: EL123991111US

TITLE: METALLOPHARMACEUTICALS FOR THE IMAGING AND TREATMENT
CANCER

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- 1.
- ☒
- Fee (Authority to charge deposit account below.)

(submit on original, and a duplicate for fee processing)

- 2.
- ☒
- Specification -----[Total Pages (212)]

(preferred arrangement set forth below)

- Descriptive title of the invention
- Cross References to Related Applications (if needed)
- Statement Regarding Fed sponsored R&D (if needed)
- Reference to Microfiche Appendix (if filed)
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s) -----[No. of Claims 51]
- Abstract of the Disclosure

- 3.
- ☐
- Drawing(s) (35 USC 113) ---[Total Pages
- ☐
- 1]

- 4.
- ☒
- Oath or Declaration -----[Total Pages
- ☐
- 2]

- a. ☐ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisions with Box 14 completed)

DELETION OF INVENTORS

Signed Statement below at 15 deleting
inventor(s) named in the prior application,
see 37 CFR 1.63(d)(2) and 1.33(b).

- 5.
- ☐
- Incorporation by Reference (useable if Box 4b is
-
- checked) The entire disclosure of the prior application,
-
- which a copy of the oath or declaration is supplied
-
- under Box 4b, is considered as being part of the
-
- disclosure of the accompanying application and is
-
- hereby incorporated by reference therein.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- 6.
- ☐
- Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequences Submission
-
- (if applicable, all necessary)

- a. ☐ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- 8.
- ☒
- Power of Attorney

- 9.
- ☐
- Information Disclosure Statement (IDS) /Cover
-
- Letter plus PTO-1449

- a.
- ☐
- Copies of IDS Citations ()

- 10.
- ☒
- Preliminary Amendment (See item 16. below)

- 11.
- ☒
- Return Receipt Postcard (MPEP 503)

(Should be specifically itemized)

- 12.
- ☐
- Certified Copy of Priority Document(s)

(if foreign priority is claimed)

- 13.
- ☐
- Other

14. If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part(CIP) of prior application No.: ____/____

DELETION OF INVENTOR(S) STATEMENT

- 15.
- ☐
- This application is being filed by less than all the inventors named in the prior application. In accordance with
-
- 37 CFR 1.63(d)(2) and 1.33(b), the Assistant Commissioner is requested to delete the name(s) of the following
-
- person who are not inventors of the invention being claimed in this application:

- 16.
- ☒
- Amend the specification, in accordance with MPEP 201.11, by inserting before the first line the sentence:

This application claims the benefit of U. S. Provisional Application No. 60/080,150, filed March 31, 1998 and
U.S. Provisional Application No. 60/112,715 filed December 18, 1998.--

- 17.
- ☐
- Priority of foreign application No. _____ filed on _____ in
-
- _____ is claimed under 35 U.S.C. 119.

Please type a plus sign (+) inside this box →

+

Attorney Docket No.: DM-6958

First Named Inventor: RAJOPADHYE ET AL.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	51 =	31	x \$ 18 =	\$558.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	6 =	3	x \$ 78 =	\$234.00
	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 260 =	\$0
				BASIC FEE (37 CFR 1.16(a))	+ \$760.00
				Total =	\$1,552.00

18. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 04-1928:

a. ☒ Fees required under 37 CFR 1.16

b. ☐ Fees required under 37 CFR 1.17.

19. ☐ Other:

20. CORRESPONDENCE ADDRESS

NAME:	David H. Vance, Ph.D.				
ADDRESS	DuPont Pharmaceuticals Company				
	c/o E. I. duPont de Nemours and Company				
	Legal - Patents				
	1007 Market Street				
CITY	Wilmington	STATE	Delaware	ZIP CODE	19898
COUNTRY	U.S.A.	TELEPHONE	302-695-7236	FAX	302-695-4069

21. SIGNATURE OF ATTORNEY OR AGENT REQUIRED

NAME	David H. Vance, Ph.D.	Reg. No. 38,644
SIGNATURE	<i>David H. Vance</i>	
DATE	March 30, 1999	

04-1928-11-14-1999